Molecular Markers in Peripheral Blood of Iranian Women with Breast Cancer

Abstract

A biomarker is a quantifiable laboratory measure of a disease specific biologically relevant molecule that can act as an indicator of a current or future disease state. The purpose of this study is to detect the expression of RNA biomarkers using Cytokeratin 19 (CK-19), Mammaglobin (MAM), Carcinoembryonic antigen (CEA), Mucin (MUC), C-Myc, erb-B2, a proliferation marker (Ki-67), Epidermal growth factor receptor (Her2/neu) and Estrogen receptor (ER) in Iranian women who were diagnosed with breast cancer. In this study, 90 samples; 60 cancer patients and 30 healthy controls were considered. 73.4 % patients were in stage I/II and 26.6 % were in stage III/IV. Patients were selected prior to the administration of any adjuvant systemic therapy. Total RNA extraction was obtained from peripheral blood of each patient and healthy control. Reverse transcription polymerase chain reaction (RT-PCR) method was used for detection of mRNA of the selected biomarkers of circulating breast cancer cells in blood. Molecular characterization is assessed as a method for early detection of breast cancer. For this purpose, eleven specific primers were selected and RT-PCR was used. The data of RT-PCR revealed that expression of MUC1, CK19, CEA, MAM, erbB-2, Ki67 and C-Myc biomarkers were significantly different between breast cancer patients and healthy controls. On the other hand, ERα, ERβ and Her2 markers were not significantly different between the two mentioned groups.

Assessment of Cytokeratin-19 Gene Expression in Peripheral Blood of Breast Cancer Patients and Breast Cancer Cell Lines

“…In several studies, CK19 as a marker for epithelial cells has been used in the diagnosis of CTC in peripheral blood of patients with breast cancer. 5 , 14 , 15 CK19 expression often changed in epithelial cancer, and especially, it has been widely used as a marker for the diagnosis of breast epithelial cells. 16 , 17 CK19 mRNA indicates the presence of CTCs in some cancers, especially breast cancer.…”

“…It can be an appropriate diagnostic marker for detection of tumor cells in the peripheral blood of patients with cancer. 5 , 6 In several studies, CK19 was used as a marker for the detection of cancer cells in the bone marrow, peripheral blood, and lymph nodes. 6 – 8 In addition, CK19 marker is considered as an independent prognostic indicator in patients with cancer.…”

Relationship between erb-B2 mRNA Expression in Blood and Tissue of Invasive Ductal Carcinoma Breast Cancer Patients and Clinicopathological Characteristics of the Tumors

“…erb-B2 molecular marker in peripheral blood was shown with low sensitivity (44%) and good specificity (90%), with only 12% false positive results in healthy controls, in our study. In our previous study, we found detected transcripts of erb-B2 in peripheral blood of 60 pretreated BC patients that was significantly different from 30 healthy controls (p<0.05) (Oloomi et al, 2013). In other study, plasma erb-B2 mRNA was shown in both peripheral blood of BC patients (43.3%) and healthy females (10%) (Xu et al, 2006).…”

“…F o r e r b -B 2 c D N A F o r w a r d p r i m e r 5'-CTGGTGACACAGCTTATGCCCT-3' and Reverse primer 5'-ATCCCCTTGGCAATCTGCA-3' were used. Specific primers were used for erb-B2 in our study (Oloomi et al, 2013). The RT-PCR product for GAPDH and erb-B2 was 319 and 113 base pair (bp), respectively.…”

Modulation of Molecular Biomarker Expression in Response to Chemotherapy in Invasive Ductal Carcinoma

“…Gene-expression profiling has altered previous perceptions about BC and could be considered as a new molecular diagnosis tool [ 9 , 10 ]. Moreover, a defined molecular marker coexpression panel for each patient with BC based on pathological characteristics and modulation assessment of expression level after treatment can provide personalized treatment for patients [ 11 ].…”